Download PDF
Klin Padiatr 2013; 225(06): 350-351
DOI: 10.1055/s-0033-1355391
Pictorial Essay
© Georg Thieme Verlag KG Stuttgart · New York

Crohn’s Disease in a Patient with Juvenile Idiopathic Arthritis after Starting Etanercept Therapy – Causal Link or Only Temporal Coincidence?

Morbus Crohn bei einem Patienten mit juveniler idiopathischer Arthritis unter Therapie mit Etanercept – Kausalität oder zeitliche Koinzidenz?
G. M. C. Flemming
1   Hospital for Children and Adolescents, University of Leipzig, Germany
,
G. Tóth
1   Hospital for Children and Adolescents, University of Leipzig, Germany
,
C. Gebauer
1   Hospital for Children and Adolescents, University of Leipzig, Germany
,
V. Schuster
1   Hospital for Children and Adolescents, University of Leipzig, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 October 2013 (online)

Also available at
    Permissions and Reprints

Key words

juvenile idiopathic arthritis (JIA) - inflammatory bowel disease (IBD) - Crohn’s disease (CD) - biologicals - TNFα

Schlüsselwörter

juvenile idiopathische ­Arthritis (JIA) - chronisch entzündliche Darmerkrankung (CED) - Morbus Crohn - Biologicals - TNFα

Supplementary Material

    The table 1 of this article can be found in internet as supplementary material with DOI http://dx.doi.org/10.1055/s-0033-1355391.
  • Supplementary Material
 

  • References

  • 1 Berg L, Lampa J, Rogberg S et al. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001; 60: 133-139
    CrossrefPubMedSearch in Google Scholar
  • 2 Dueckers G, Guellac N, Arbogast M et al. Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology. Klinische Padiatrie 2011; 223: 386-394
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Russell RK, Wilson DC, Satsangi J. Unravelling the complex genetics of inflammatory bowel disease. Arch Dis Child 2004; 89: 598-603
    CrossrefPubMedSearch in Google Scholar
  • 4 Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094
    CrossrefPubMedSearch in Google Scholar
  • 5 Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426
    CrossrefPubMedSearch in Google Scholar
  • 6 Toussirot E, Houvenagel E, Goeb V et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine. 2011
    PubMedSearch in Google Scholar
  • 7 van Dijken TD, Vastert SJ, Gerloni VM et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011; 38: 1441-1446
    CrossrefPubMedSearch in Google Scholar
  • 8 Zou J, Rudwaleit M, Brandt J et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62: 561-564
    CrossrefPubMedSearch in Google Scholar